Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2008121877) CFTR INHIBITOR COMPOUNDS AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2008/121877 International Application No.: PCT/US2008/058752
Publication Date: 09.10.2008 International Filing Date: 28.03.2008
IPC:
C07C 251/86 (2006.01) ,C07C 311/00 (2006.01) ,C07C 317/44 (2006.01) ,C07C 323/60 (2006.01) ,C07D 231/06 (2006.01) ,C07D 231/14 (2006.01) ,C07D 237/04 (2006.01) ,A61K 31/415 (2006.01) ,A61K 31/495 (2006.01) ,A61P 9/06 (2006.01) ,A61P 1/12 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
251
Compounds containing nitrogen atoms doubly- bound to a carbon skeleton
72
Hydrazones
86
having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
311
Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
317
Sulfones; Sulfoxides
44
having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
323
Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
50
containing thio groups and carboxyl groups bound to the same carbon skeleton
51
having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
60
with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
231
Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
02
not condensed with other rings
06
having one double bond between ring members or between a ring member and a non-ring member
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
231
Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
02
not condensed with other rings
10
having two or three double bonds between ring members or between ring members and non-ring members
14
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
237
Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
02
not condensed with other rings
04
having less than three double bonds between ring members or between ring members and non-ring members
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
415
1,2-Diazoles
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
06
Antiarrhythmics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1
Drugs for disorders of the alimentary tract or the digestive system
12
Antidiarrhoeals
Applicants:
RUSSELL, Michael Geoffrey Neil [GB/GB]; GB (UsOnly)
VATER, Huw David [GB/GB]; GB (UsOnly)
MACRITCHIE, Jacqueline Anne [GB/GB]; GB (UsOnly)
DOYLE, Kevin James [GB/GB]; GB (UsOnly)
BROWN, David [GB/GB]; US (UsOnly)
PEACH, Joanne [GB/GB]; GB (UsOnly)
INSTITUTE FOR ONEWORLD HEALTH [US/US]; 50 California Street, Suite 500 San Francisco, California 94111, US (AllExceptUS)
Inventors:
RUSSELL, Michael Geoffrey Neil; GB
VATER, Huw David; GB
MACRITCHIE, Jacqueline Anne; GB
DOYLE, Kevin James; GB
BROWN, David; US
PEACH, Joanne; GB
Agent:
SWISS, Gerald F. ; FOLEY & LARDNER LLP 975 Page Mill Road Palo Alto, California 94304-1013, US
Priority Data:
60/909,64302.04.2007US
Title (EN) CFTR INHIBITOR COMPOUNDS AND USES THEREOF
(FR) COMPOSÉS INHIBITEURS DE CFTR ET LEURS UTILISATIONS
Abstract:
(EN) The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-6 or encompassed by formulas I-VI) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.
(FR) La présente invention concerne des compositions et des procédés de traitement d'une maladie chez un animal, ladite maladie répondant à l'inhibition d'un polypeptide régulateur de la conduction transmembranaire de la fibrose kystique fonctionnelle (CFTR) par l'administration à un mammifère qui en a besoin, d'une quantité efficace d'un composé défini dans celle-ci (comprenant les composés définis dans les tableaux 1 à 6 ou compris dans les formules I à VI) ou des compositions de ceux-ci, traitant ainsi la maladie. La présente invention concerne en particulier un procédé de traitement des diarrhées et de la maladie rénale polykystique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)